Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of PEG recombinant human growth hormone injection in idiopathic short stature
ChiCTR2400085430Phase 4Not yet recruiting
- Sponsor
- Huangshi Maternal and Child Health Hospital
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of genotropin miniquick in Idiopathic Short Stature (ISS), sponsored by Huangshi Maternal and Child Health Hospital. Primary endpoints: Change in height SDS at 12 months and Increase in height at 12 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
genotropin miniquick
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on ChiCTR2400085430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085430.